Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1929 Target Snapshot

Xanthine dehydrogenase/oxidase · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,074Compounds
174Assays
6Approved Drugs
1,106.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Xanthine dehydrogenase/oxidase shows approved-linked disease relevance led by hyperuricemia. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P47989. Start with hyperuricemia, then reuse UniProt P47989 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with hyperuricemia, then reuse UniProt P47989 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 3 linked drugs
Open source guide
Disease program
hyperuricemia

Xanthine dehydrogenase/oxidase shows approved-linked disease relevance led by hyperuricemia. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with hyperuricemia because it currently carries approved-linked support. Linked drugs include ALLOPURINOL, FEBUXOSTAT, TOPIROXOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Xanthine dehydrogenase/oxidase as ChEMBL target CHEMBL1929, mapped to UniProt P47989. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Xanthine dehydrogenase/oxidase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1929
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P47989
Xanthine dehydrogenase/oxidase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Xanthine dehydrogenase/oxidase is the right protein anchor across sources, using UniProt P47989 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why hyperuricemia is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameXanthine dehydrogenase/oxidase
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP47989
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelXanthine dehydrogenase/oxidase
UniProt AccessionP47989
Component TypeProtein
Sequence Length1333 aa

Xanthine dehydrogenase/oxidase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Xanthine dehydrogenase/oxidase, mapped to UniProt P47989. Sequence length is 1333 aa.

Mapped IDP47989
Review nameXanthine dehydrogenase/oxidase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Xanthine dehydrogenase/oxidase shows approved-linked disease relevance led by hyperuricemia. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
hyperuricemia
3 linked drugs · 3 direct · 3 efficacy
Linked drugALLOPURINOL
Linked drugFEBUXOSTAT
Linked drugTOPIROXOSTAT
Approved-linked Approved
gout
2 linked drugs · 2 direct · 2 efficacy
Linked drugALLOPURINOL
Linked drugFEBUXOSTAT
Approved-linked Approved
Arthralgia
1 linked drug · 1 direct · 1 efficacy
Linked drugBENDAZAC
Approved-linked Approved
cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugALLOPURINOL
Approved-linked Approved
eye inflammation
1 linked drug · 1 direct · 1 efficacy
Linked drugBENDAZAC
Approved-linked Approved
gout
1 linked drug · 1 direct · 1 efficacy
Linked drugFEBUXOSTAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with hyperuricemia because it currently carries approved-linked support. Linked drugs include ALLOPURINOL, FEBUXOSTAT, TOPIROXOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasehyperuricemia
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

6
Approved
4
Phase III
9
Phase II
1
Phase I
1
Phase 0.5
Assay Mix

Activity Type Distribution

IC501,042.0
KI64.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5911881 10.82 IC50 0.015 Preclinical
CHEMBL5395750 10.7 IC50 0.02 Preclinical
CHEMBL5893388 10.54 IC50 0.029 Preclinical
CHEMBL5753958 10.4 IC50 0.04 Preclinical
CHEMBL5765459 10.4 IC50 0.04 Preclinical
CHEMBL5765233 10.22 IC50 0.06 Preclinical
CHEMBL5886087 10.22 IC50 0.06 Preclinical
CHEMBL5919922 10.22 IC50 0.06 Preclinical
CHEMBL5947643 10.19 IC50 0.064 Preclinical
CHEMBL5803335 10.15 IC50 0.07 Preclinical
Distribution

pChEMBL Value Distribution

104
5.0
93
5.5
100
6.0
76
6.5
88
7.0
52
7.5
47
8.0
42
8.5
12
9.0
10
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEBUXOSTAT
CHEMBL1164729
Approved 2008
Properties Compare Identifier
ALLOPURINOL
CHEMBL1467
Approved 1966
Properties Compare Identifier
Assay Landscape

Assay Landscape

174
Total Assays
682
Tested Compounds
1
Assay Types
Binding — 174 assays, 682 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 169 637 6.3
assay format 3 45 6.8
cell-based format 1 0 —
tissue-based format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine